Kericure Inc., a biotechnology company specializing in wound care products, has been awarded a $3,111,212 definite-price contract by the Department of the Army Medical Command. This contract, set aside for total small businesses, will fund Kericure Medical Division to conduct Phase III clinical validation of a portable, ruggedized antimicrobial wound dressing for management of large surface area burns over prolonged field care and long-term care situations. The dressing aims to support the Army's medical research goals for treating combat injuries. Leveraging its expertise in nanopolymer technology, Kericure has previously received SBIR awards from the Army Medical Command and Joint PEO Chemical and Biological Defense totaling $3.5 million to develop deployable wound care products and further mature related technologies.
Generated 3/11/24, 9:03 AM